This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Punit Seth, PhD
SVP, Research at Alnylam Pharmaceuticals

Profile

Prior to his current position at Alnylam, Dr. Punit Seth headed medicinal chemistry and targeted delivery at Ionis Pharmaceuticals. He is co-inventor of Ionis’ Gen 2.5, next-generation chemistry, and LICA (ligand conjugated antisense oligonucleotides) platforms which enhance potency, safety and duration of ASO drugs. Dr. Seth pioneered the use of cyclic peptide ligands targeting the Transferrin receptor 1 to enhance potency of RNA therapeutics in skeletal muscle and heart tissues. He is listed as co-author/co-inventor on over 220 peer-reviewed publications, issued patents and patent applications. Dr. Seth has a Ph.D in organic chemistry from The Ohio State University.

Agenda Sessions

  • Chairman’s Remarks: New Technologies for Targeting RNA and Genomic DNA

    8:25am